Britta Majchrzak-Stiller

6PUBLICATIONS
10CO-AUTHORS
Liquid biopsiesPredictive and prognostic markersGene and molecular therapyMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Oct 07, 2026
Bile does not increase the aggressiveness of pancreatic fluid towards fibrin-based sealants in a short-term ex-vivo setting.

|Jul 27, 2024
Maintenance Therapy for Pancreatic Cancer, a New Approach Based on the Synergy between the Novel Agent GP-2250 (Misetionamide) and Gemcitabine.

Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters

|Oct 28, 2023
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes.

Thilo Gambichler, Friederike Harnischfeger, Marina Skrygan

|Jun 30, 2023
GP-2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP-Kinase and impairs the NF-kB pathway in pancreatic cancer cells.

Britta Majchrzak-Stiller, Marie Buchholz, Ilka Peters

|Jul 09, 2022
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study.

Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller

|Jun 10, 2022
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas-The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo.

Marie Buchholz, Johanna Strotmann, Britta Majchrzak-Stiller

Pageof 1

Frequent Collaborators

3 joint publications

Marie Buchholz

3 joint publications

Ilka Peters

2 joint publications

Stephan Hahn

2 joint publications

Philipp Höhn